Page 18 - Demo

Journal of Rural Medicine%u4e61%u6751%u533b%u5b66%u7b2c 2 %u5377%u25c6%u7b2c 4 %u671f%u25c6%u7248%u672c 1.0 %u25c6 2025 %u5e74%u6587%u7ae0%u7c7b%u578b%uff1a%u8bba%u6587 | %u520a%u53f7%uff08ISSN%uff09%uff1a3060-947X12 Copyright %u00a9 This work is licensed under a Commons Attibution-Non Commercial 4.0 International License.of amisulpride steady-state plasma concentration in patients withschizophrenia in real-life settings based on therapeutic drug monitoringdata[J]. Asian J Psychiatr, 2023, 87(1): 103699.[14] Mauri M C, Volonteri L S, Colasanti A, et al. Clinicalpharmacokinetics of atypical antipsychotics: a critical review of therelationship between plasma concentrations and clinical response[J]. ClinPharmacokinet, 2007, 46(5): 359-388.[15] Li L, Li L, Shang D W, et al. A systematic review andcombined meta-analysis of concentration of oral amisulpride[J]. Br JClin Pharmacol, 2020, 86(4): 668-678.[16] M%u00fcller M J, Regenbogen B, Sachse J, et al. Gender aspects inthe clinical treatment of schizophrenic inpatients with amisulpride: atherapeutic drug monitoring study[J]. Pharmacopsychiatry, 2006, 39(2): 41-46.[17] J%u00f6nsson A K, Spigset O, Reis M. A Compilation of SerumConcentrations of 12 Antipsychotic Drugs in a Therapeutic DrugMonitoring Setting[J]. Ther Drug Monit, 2019, 41(3): 348-356.[18] Bergemann N, Kopitz J, Kress K R, et al. Plasmaamisulpride levels in schizophrenia or schizoaffective disorder[J]. EurNeuropsychopharmacol, 2004, 14(3): 245-250.[19] Yang S, Wang H, Zheng G F, et al. Age, Sex, andComedication Effects on the Steady-State Plasma Concentrations ofAmisulpride in Chinese Patients with Schizophrenia[J]. Ther DrugMonit, 2023, 45(5): 676-682.[20] %u738b%u6bc5%u5947%uff0c%u5e38%u8def%u7476%uff0c%u4ed8%u5189%uff0c%u7b49 . %u57fa%u4e8e%u6cbb%u7597%u836f%u7269%u76d1%u6d4b%u7684%u6c28%u78fa%u5fc5%u5229%u5242%u91cf%u6821%u6b63%u6d53%u5ea6%u5f71%u54cd%u56e0%u7d20%u5206%u6790 [J]. %u4e2d%u56fd%u836f%u623f%uff0c2022%uff0c33(24)%uff1a3020-3024.[21] Sun F, Yu F, Gao Z, et al. Study on the relationship amongdose, concentration and clinical response in Chinese schizophrenicpatients treated with Amisulpride[J]. Asian J Psychiatr, 2021, 62: 102694.[22] %u738b%u5360%u748b%uff0c%u502a%u6653%u4f73%uff0c%u5362%u6d69%u626c%uff0c%u7b49 . %u6c28%u78fa%u5fc5%u5229%u7247%u6cbb%u7597%u836f%u7269%u76d1%u6d4b%u53ca%u4e34%u5e8a%u5e94%u7528%u7814%u7a76 [J]. %u4e2d%u56fd%u4e34%u5e8a%u836f%u7406%u5b66%u6742%u5fd7%uff0c2018%uff0c34(23): 2704-2706+2710.[23] %u5218%u6e05%u971e%uff0c%u4e8e%u5fd7%u519b%uff0c%u51af%u5b87%u5a77 . %u7cbe%u795e%u5206%u88c2%u75c7%u60a3%u8005%u6c28%u78fa%u5fc5%u5229%u8840%u836f%u6d53%u5ea6%u76d1%u6d4b%u7ed3%u679c%u53ca%u5f71%u54cd%u56e0%u7d20%u5206%u6790 [J]. %u5317%u65b9%u836f%u5b66%uff0c2022%uff0c19(3): 136-138.[24] Glatard A, Guidi M, Delacr%u00e9taz A, et al. Amisulpride: Real-World Evidence of Dose Adaptation and Effect on ProlactinConcentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses[J]. Clin Pharmacokinet, 2020, 59(3): 371-382.[25] %u6881%u82f1%uff0c%u5218%u767b%u5802%uff0c%u53f8%u5929%u6885%uff0c%u7b49 . %u6c28%u78fa%u5fc5%u5229%u6cbb%u7597%u7cbe%u795e%u5206%u88c2%u75c7%u4e34%u5e8a%u5e94%u7528%u4e13%u5bb6%u610f%u89c1 [J]. %u4e2d%u56fd%u5fc3%u7406%u536b%u751f%u6742%u5fd7%uff0c2017%uff0c31(6)%uff1a425-431.[26] Schmitt U, Abou El-Ela A, Guo L J, et al. Cyclosporine A(CsA) affects the pharmacodynamics and pharmacokinetics of the atypicalantipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)[J]. J Neural Transm (Vienna), 2006, 113(7): 787-801.[27] H%u00e4rtter S, H%u00fcwel S, Lohmann T, et al. How does the benzamideantipsychotic amisulpride get into the brain?--An in vitro approachcomparing amisulpride with clozapine[J]. Neuropsychopharmacology, 2003, 28(11): 1916-1922.[28] Sekhar G N, Fleckney A L, Boyanova S T, et al. Regionspecific blood-brain barrier transporter changes leads to increasedsensitivity to amisulpride in Alzheimer%u2019s disease[J]. Fluids BarriersCNS, 2019, 16(1): 38.[29] Taurines R, Fekete S, Preuss-Wiedenhoff A, et al. Therapeuticdrug monitoring in children and adolescents with schizophrenia and otherpsychotic disorders using risperidone[J]. J Neural Transm (Vienna), 2022, 129(5-6): 689-701.[30] Warrings B, Samanski L, Deckert J, et al. Impact of Body MassIndex on Serum Concentrations of Antidepressants and Antipsychotics[J]. Ther Drug Monit, 2021, 43(2): 286-291.[31] Brill M J, Diepstraten J, Van Rongen A, et al. Impact of obesityon drug metabolism and elimination in adults and children[J]. Clin